UPLC–MS for metabolomics: a giant step forward in support of pharmaceutical research

Drug Discovery Today

Volumn 22, Issue 2, 2017, Pages 463-470

  Nassar, Ala F ^a,b   Wu, Terence ^c   Nassar, Samuel F ^a   Wisnewski, Adam V ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

^c YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

DRUG DEVELOPMENT; DRUG RESEARCH; HUMAN; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; MASS FRAGMENTOGRAPHY; METABOLITE; METABOLOMICS; NUCLEAR MAGNETIC RESONANCE; REVIEW; STUDY DESIGN; ANIMAL; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY;

ANIMALS; CHROMATOGRAPHY, LIQUID; DRUG DISCOVERY; HUMANS; MASS SPECTROMETRY; METABOLOMICS; PHARMACEUTICAL RESEARCH;

EID: 85008439754     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2016.11.020     Document Type: Review

References (56)

1. 1 Nicholson, J.K., Lindon, J.C., Systems biology: metabonomics. Nature 455 (2008), 1054–1056.
2. 2 Pauling, L., et al. Quantitative analysis of urine vapor and breath by gas liquid partition chromatography. Proc. Natl. Acad. Sci. U. S. A. 68 (1971), 2374–2376.
3. 3 Devaux, P.G., et al. Benyzloxime derivative of steroids, a new metabolic profile procedure for human urinary steroids. Anal. Lett., 4, 1971, 151.
4. 4 Horning, B.C., Horning, M.G., Human metabolic profiles obtained by GC and GC/MS. J. Chromatogr. Sci. 9 (1971), 129–140.
5. 5 Gates, S.C., Sweeley, C.C., Quantitative metabolic profiling based on gas chromatography. Clin. Chem. 24 (1978), 1663–1673.
6. 6 Lindon, J.C., et al. The Consortium for Metabonomic Toxicology (COMET): aims, activities and achievements. Pharmacogenomics 6 (2005), 691–699.
7. 7 Sun, H., et al. Metabolomic analysis of key regulatory metabolites in hepatitis C virus-infected tree shrews. Mol. Cell. Proteomics 12 (2013), 710–719.
8. 8 Kaddurah-Daouk, R., et al. Metabolomics: a global biochemical approach to drug response and disease. Annu. Rev. Pharmacol. Toxicol. 48 (2008), 653–683.
9. 9 Collino, S., et al. Clinical metabolomics paves the way towards future healthcare strategies. Br. J. Clin. Pharmacol. 75 (2013), 619–629.
10. 10 van Ravenzwaay, B., et al. The use of metabolomics for the discovery of new biomarkers of effect. Toxicol. Lett. 172 (2007), 21–28.
11. 11 Mirsaeidi, M., et al. Metabolomics: applications and promise in mycobacterial disease. Ann. Am. Thorac. Soc. 12 (2015), 1278–1287.
12. 12 Puchades-Carrasco, L., Pineda-Lucena, A., Metabolomics in pharmaceutical research and development. Curr. Opin. Biotechnol. 35 (2015), 73–77.
13. 13 Adamko, D.J., et al. A pilot study differentiating diseases. J. Allergy Clin. Immunol. 136 (2015), 571–580.
14. 14 Vanisevic, J., Siuzdak, G., The role of metabolomics in brain metabolism research. J. Neuroimmune Pharmacol. 10 (2015), 391–395.
15. 15 Vuckovic, D., Current trends and challenges in sample preparation for global metabolomics using liquid chromatography–mass spectrometry. Anal. Bioanal. Chem. 403 (2012), 1523–1548.
16. 16 Reily, M.D., et al. LC–MS in endogenous metabolite profiling and small molecule biomarker discovery. Lee, M.S., Zhu, M., (eds.) Mass Spectrometry in Drug Metabolism and Disposition: Basic Principles and Applications, 2011, John Wiley & Sons, 685–722.
17. 17 Guo, B., et al. Liquid chromatography–mass spectrometric multiple reaction monitoring-based strategies for expanding targeted profiling towards quantitative metabolomics. Curr. Drug Metab. 13 (2012), 1226–1243.
18. 18 Lei, Z., et al. Mass spectrometry strategies in metabolomics. J. Biol. Chem. 286 (2011), 25435–25442.
19. 19 Ward, J.L., et al. Recent applications of NMR spectroscopy in plant metabolomics. FEBS J. 274 (2007), 1126–1131.
20. 20 Lu, W., et al. Analytical strategies for LC–MS-based targeted metabolomics. J. Chromatogr. B 871 (2008), 236–242.
21. 21 Mishur, R.J., Rea, S.L., Applications of mass spectrometry to metabolomics and metabonomics: detection of biomarkers of aging and of age-related diseases. Mass Spectrom. Rev. 31 (2012), 70–95.
22. 22 Martin, J-C., et al. Can we trust untargeted metabolomics? Results of the metaboring initiative, a large-scale, multi-instrument inter-laboratory study. Metabolomics 11 (2015), 807–821.
23. 23 Nassar, A-E.F., et al. Learning to improve the decision-making process in structural modification of drug candidates: reduce toxicity. Drug Discov. Today 9 (2004), 1055–1064.
24. 24 Nassar, A-E.F., Talaat, R., Strategies for dealing with metabolite elucidation in drug discovery and development. Drug Discov. Today 9 (2004), 317–327.
25. 25 Nassar, A-E.F., Adams, P.E., Metabolite characterization in drug discovery utilizing robotic liquid-handling, quadrupole time-of-flight mass spectrometry and in silico prediction. Curr. Drug Metab. 4 (2003), 259–271.
26. 26 Verhoeckx, K.C., et al. In search of secreted protein biomarkers for the anti-inflammatory effect of beta2-adrenergic receptor agonists: application of DIGE technology in combination with multivariate and univariate data analysis tools. J. Proteome Res. 4 (2005), 2015–2023.
27. 27 Clarke, J., et al. Characterization of hepatocellular carcinoma-related genes and metabolites in human nonalcoholic fatty liver disease. Dig. Dis. Sci. 59 (2014), 365–374.
28. 28 Forgue, P., et al. NMR metabolic profiling of Aspergillus nidulans to monitor drug and protein activity. J. Proteome Res. 5 (2006), 1916–1923.
29. 29 Mahgoub, A., et al. Polymorphic hydroxylation of debrisoquine in man. Lancet 17 (1977), 584–586.
30. 30 Dorado, P., et al. Dermination of debrisoquine and 4-hydroxydebrisoquine by high-performance liquid chromatography: application to the evaluation of CYP2D6 genotype and debrisoquine metabolic ratio relationship. Clin. Chem. Lab. Med. 43 (2005), 259–275.
31. 31 Cho, J.Y., et al. Urinary metabolomics in Fxr-null mice reveals activated adaptive metabolic pathways upon bile acid challenge. J. Lipid Res. 51 (2010), 1063–1074.
32. 32 Goodsaid, F.M., et al. The Predictive Safety Testing Consortium: a synthesis of the goals, challenges and accomplishments of the Critical Path. Drug Discov. Today: Technol. 2 (2007), 47–50.
33. 33 Finkelstein, J.B., FDA starts moving on Critical Path, but initiative running out of steam. JNCI 99 (2007), 426–427.
34. 34 Altar, C.A., The Biomarkers Consortium: on the critical path of drug discovery. Clin. Pharmacol. Ther. 83 (2008), 361–364.
35. 35 Mortshire-Smith, R.J., et al. Use of metabonomics to identify impaired fatty acid metabolism as the mechanism of a drug-induced toxicity. Chem. Res. Toxicol. 17 (2004), 165–173.
36. 36 Ritchie, S.A., et al. Metabolic system alterations in pancreatic cancer patient serum: potential for early detection. BMC Cancer, 13, 2013, 416.
37. 37 Tabak, A.G., et al. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet 373 (2009), 2215–2221.
38. 38(a) Wang, T.J., et al. Metabolite profiles and the risk of developing diabetes. Nat. Med. 17 (2011), 448–453.
39. 38(b) Surveillance, Epidemiology, and End Results (SEER) Program ( www.seer.cancer.gov) Research Data, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2015.
40. 39 Wishart, D.S., Emerging applications of metabolomics in drug discovery and precision medicine. Nat. Rev. Drug Discov. 15 (2016), 473–484.
41. 40 Struys, E.A., et al. Serum sarcosine is not a marker for prostate cancer. Ann. Clin. Biochem., 47, 2010, 282.
42. 41 Ma, J., et al. Metformin enhances tamoxifen-mediated tumor growth inhibition in ER-positive breast carcinoma. BMC Cancer, 14, 2014, 172.
43. 42 Wisnewski, A.V., et al. Isocyanate vapor-induced antigenicity of human albumin. J. Allergy Clin. Immunol. 113 (2004), 1178–1184.
44. 43 Yang, M., et al. Oncometabolites: linking altered metabolism with cancer. J. Clin. Investig. 123 (2013), 3652–3658.
45. 44 Yang, M., The emerging role of fumarate as an oncometabolite. Front. Oncol., 2, 2012, 85.
46. 45 Morin, A., Oncometabolites-driven tumorigenesis: from genetics to targeted therapy. Int. J. Cancer 135 (2014), 2237–2248.
47. 46 Khan, A.P., et al. The role of sarcosine metabolism in prostate cancer progression. Neoplasia 15 (2013), 491–501.
48. 47 Chen, K.T., et al. AMPA receptor–mTOR activation is required for the antidepressant-like effects of sarcosine during swim tests in rats: insertion of AMPA receptor may play a role. Front. Behav. Neurosci., 9, 2015, 162.
49. 48 Lee, A.S., Glucose-regulated proteins in cancer: molecular mechanisms and therapeutic potential. Nat. Rev. Cancer 14 (2014), 263–276.
50. 49 Wolf, A., et al. Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. J. Exp. Med. 208 (2011), 313–326.
51. 50 Wise, D.R., Thompson, C.B., Glutamine addiction: a new therapeutic target in cancer. Trends Biochem. Sci. 35 (2010), 427–433.
52. 51 Miller, D.M., et al. c-Myc and cancer metabolism. Clin. Cancer Res. 18 (2012), 5546–5553.
53. 52 Zhang, J., et al. Asparagine plays a critical role in regulating cellular adaptation to glutamine depletion. Mol. Cell 56 (2014), 205–218.
54. 53 Awwad, H.M., et al. The role of choline in prostate cancer. Clin. Biochem. 45 (2012), 1548–1553.
55. 54 Choi, S.Y., et al. Cancer-generated lactic acid: a regulatory, immunosuppressive metabolite?. J. Pathol. 230 (2013), 350–355.
56. 55 Gillies, R.J., Gatenby, R.A., Metabolism and its sequelae in cancer evolution and therapy. Cancer J. 21 (2015), 88–96.